Tech Neck, Meet the FDA

Your Phone Became the Villain

Sometime in the last two years, the neck became the face's anxious younger sibling. You know the genre of content by now: a creator tilts their chin down toward an imaginary phone, the horizontal creases above the collarbone deepen on cue, and a caption announces that this — this — is what your screen habit is doing to you. The term "tech neck" went from a physical-therapy complaint about posture and shoulder pain to a skincare diagnosis about wrinkles, and the beauty industry moved in fast.¹⁴

Olay ran a campaign built around the phrase. RoC pushed a neck serum and reported a double-digit jump in serum sales off the back of the messaging.¹⁴ TikTok filled with neck-taping hacks, "neck training" routines, and before-and-afters. The premise was tidy and frightening in equal measure: a modern habit was carving permanent lines into a part of the body nobody used to think about, and you needed to buy something to fix it.

Then, on June 16, 2026, the story got its centerpiece. Allergan Aesthetics, the AbbVie division behind Botox and Juvéderm, announced that the FDA had approved SKINVIVE by Juvéderm "to reduce neck lines for the improvement of neck appearance in adults over the age of 21."¹ The first injectable cleared specifically for the neck. The headlines wrote themselves, and most of them used the words "tech neck."

So let's do what we do here. There are two separate claims tangled together in this announcement, and they deserve very different grades. One is a regulatory fact backed by a real, if modest, clinical trial. The other is a marketing narrative backed by essentially nothing. Pulling them apart is the whole job.

What the FDA Actually Signed Off On

Start with the part that is unambiguously true. SKINVIVE is now FDA-approved for the neck. This is the product's second indication; it was first cleared in May 2023 for "improving skin smoothness of the cheeks," where it became the first injectable in the United States marketed for "skin quality" rather than for filling a line or adding volume.² The neck approval extends that idea to a new location.

A detail the press coverage mostly skipped: SKINVIVE is regulated as a medical device, not a drug. Hyaluronic acid dermal fillers fall under the FDA's device pathway, and this clearance came through a supplemental premarket approval (sPMA) attached to the original filler's PMA file. The FDA accepted the supplement for review on June 30, 2025, and approved it roughly eleven and a half months later.⁴ That distinction matters when you read coverage that talks about a "PDUFA date" — that's drug-review language, and it doesn't apply here.

The approval also came with strings. The FDA required Allergan to run a provider training program; injectors have to complete it before they can buy or administer the product for the neck.¹ That's a signal that the agency sees the neck as a higher-stakes injection site than the cheek, which — as we'll get to — it is.

Here is the sentence the marketing tends to blur: the FDA approved SKINVIVE to improve the appearance of existing horizontal neck lines. It did not approve any claim about what causes those lines, and it certainly did not bless the idea that your phone is responsible for them. An approval is a statement about whether a treatment safely does what its trial measured. This trial measured line improvement. It did not measure phones.

Not a Filler. A Sponge.

If you picture a dermal filler, you probably picture a gel injected deep to plump a fold or build a cheekbone. SKINVIVE is not that, even though it's made of the same base material. Internationally it's sold as Juvéderm Volite, and to chemists it's VYC-12L: a modified hyaluronic acid at 12 milligrams per milliliter, crosslinked with BDDE, blended with 0.3% lidocaine to dull the sting.¹⁰ It belongs to Allergan's Vycross platform — a blend of high- and low-molecular-weight HA chains — but it's the softest, most spreadable gel in that family, deliberately engineered not to hold its shape.

Instead of being placed deep to lift, it's injected as tiny intradermal microdroplets spread across the skin. There it behaves less like scaffolding and more like a network of microscopic sponges. Hyaluronic acid is intensely water-loving; each droplet pulls in and holds moisture, and the cumulative effect is skin that reads as smoother, more hydrated, and — in the brochure language — "glowier."² The company points to mechanistic work suggesting the treatment nudges up aquaporin, a cellular water channel, alongside skin-explant data on hydration markers.^8,9

This is the concept the industry calls a "skin booster" or "skin quality" injectable, and it's worth understanding because it sets the ceiling on what SKINVIVE can plausibly do. A hydration depot can soften the look of fine, superficial lines. It is not a muscle relaxant and not a volumizer, so it is not going to erase deep vertical neck cords or lift sagging skin. Keep that ceiling in mind, because the before-and-afters circulating online don't always respect it.

74.8% of 105 People

Now the trial. The neck approval rests on a single randomized, multicenter, evaluator-blinded pivotal study of 105 treated participants.^1,4 Improvement was graded on the Allergan Transverse Neck Lines Scale, a five-point photonumeric scale where a trained, blinded evaluator scores the severity of the horizontal creases. The bar for "success" was a one-point improvement on that scale.

For context, the original cheek study followed the same template and is the more transparent of the two because it was published in a peer-reviewed journal. In Dermatologic Surgery in 2023, Macrene Alexiades and colleagues reported that 58% of treated cheeks improved by at least one point on the Allergan Cheek Smoothness Scale at one month, versus just 4.5% of untreated controls, with 56% still responding at six months.⁶ Patient-satisfaction scores climbed substantially — 83% satisfied with skin "health" at six months, up from 38% at baseline.⁷ The lead investigator was an Allergan-compensated consultant, which is standard for industry trials but worth naming.

So what do we actually have? A real treatment effect, measured by blinded evaluators against a control, replicated across two body sites by the same company. That is more than most viral skincare ingredients can claim, and I want to give it its due. But it is also a single small neck trial, funded and run by the company that profits from the answer, with a modest endpoint and a six-month shelf life. "It works" and "it works dramatically and forever" are different sentences. This is the first one.

Did Your Phone Actually Do This?

Here is where the marketing and the evidence part ways completely. Search the dermatology literature for proof that looking down at a phone causes horizontal neck lines and you will find a striking absence: no controlled human study demonstrates it. Not a randomized trial, not a cohort study, not even a decent dose-response analysis linking screen time to neck-line incidence or severity. The idea is biomechanically plausible — repeatedly folding skin could, in theory, contribute to creasing — but plausible is not the same as proven, and in this case the proof simply hasn't been produced.¹⁴

What we do know about horizontal neck lines points elsewhere. They're driven by ordinary intrinsic aging, as neck skin thins and loses collagen and elastin; by photoaging, because the neck is one of the most chronically sun-exposed and least sunscreened areas on the body; by genetics; by weight change; and by sleep creases. Tellingly, horizontal neck lines often show up early — many people have them in childhood or young adulthood, as congenital tension lines that have nothing to do with any device.

There's also a definitional sleight of hand worth flagging. "Neck aging" lumps together at least three different things: the horizontal lines SKINVIVE targets, the vertical platysmal bands that come from a muscle and are treated with neurotoxin, and general sagging and laxity that no skin booster can address. Marketing that shows a phone causing a problem and an injectable solving it tends to slide between these categories, because the more problems "tech neck" seems to cause, the bigger the market.

Even the company is more careful than its fans. Allergan's own release lists the causes of neck lines as "natural aging, sun damage, weight loss, or tech-neck" — placing the phone as one item on a list, not the headline.¹ Independent dermatologists have been blunter. Dr. Shereene Idriss has warned that the trend is largely "perception versus reality," and others note that every generation has blamed the era's habits for the same aging neck.¹⁴ The most a sympathetic reading supports is that screen posture might make pre-existing lines look more pronounced. That is a long way from "your phone is destroying your neck."

What They Didn't Study

A few things about this approval deserve more attention than they've gotten, because they shape who should think twice.

On the everyday side, the trial's adverse events were the familiar injectable list: redness, bruising, tenderness, swelling, lumps, firmness, and itching at the injection sites, mostly mild, generally resolving within about two weeks without treatment. Severe adverse events occurred in fewer than 5% of those reporting events.¹ That's a reassuring short-term profile. The longer-tail risks — delayed nodules months later, and the catastrophic-but-rare vascular events common to all fillers — depend heavily on who's holding the needle.¹²

One more piece of context for the "first and only" framing, which is accurate but narrow. SKINVIVE is the first HA injectable the FDA has approved for the neck, full stop. But skin boosters aren't new internationally: Profhilo, a hybrid HA "bioremodeler" that claims to stimulate collagen and elastin, has been used off-label on necks for years and is not FDA-approved.¹³ SKINVIVE's regulatory moat is real. Its mechanism — hydration, not bioremodeling — is genuinely different from Profhilo's pitch, and neither has the long-term comparative data to crown a winner.

The Verdict